NCT01969032View on ClinicalTrials.gov

Induction Preoperative Chemotherapy for Patients With Locally Advanced Triple Negative Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

May 31, 2014

Study Completion Date

September 30, 2014

Conditions
Triple Negative Breast Cancer
Interventions
DRUG

Paclitaxel, Carboplatinum, Doxorubicin, Endoxan, Capecitabine

Paclitaxel 60 mg/m2 IV weekly plus Carboplatinum AUC2 IV weekly for 9 weeks, then Doxorubicin 25 mg/m2 IV weekly plus Endoxan 50 mg per os q.i.d. plus Capecitabine 500 mg t.i.d for 9 weeks

Trial Locations (1)

115478

Russian Cancer Research Center named after N.N.Blokhin RAMS, Moscow

All Listed Sponsors
lead

Russian Academy of Medical Sciences

OTHER

NCT01969032 - Induction Preoperative Chemotherapy for Patients With Locally Advanced Triple Negative Breast Cancer | Biotech Hunter | Biotech Hunter